Morgan Stanley initiated coverage of CG Oncology with an Overweight rating and $55 price target. The firm notes that interim data for cretostimogene have been compelling, suggesting it is as good or better than approved or developmental candidates for bladder cancer. Morgan Stanley further points out that multiple data readouts and milestones are expected in 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CGON: